Status:

COMPLETED

Single Session of tACS in a Depressive Episode

Lead Sponsor:

University of North Carolina, Chapel Hill

Collaborating Sponsors:

National Institute of Mental Health (NIMH)

Conditions:

Depression

Major Depressive Disorder

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

Purpose: Investigating the effects of non-invasive transcranial alternating current stimulation (tACS) on healthy participants and participants with mood disorders. Participants: 40 males and females...

Detailed Description

Participants will report for a study visit and will review and sign a consent form. Participants will complete several clinical assessments and also take a urine drug test and urine pregnancy test (i...

Eligibility Criteria

Inclusion

  • Inclusion Criteria for individuals with depressed mood:
  • Ages 18-65 years
  • Hamilton Depression Rating Scale score \>8
  • Capacity to understand all relevant risks and potential benefits of the study (informed consent)
  • Low suicide risk which will be determined through the use of both the Structured Clinical Interview for the DSM-5 and by scoring less than 3 (0,1, or 2) in the Hamilton rating depression scale.
  • Negative pregnancy test for female participants
  • Exclusion Criteria for individuals with depressed mood:
  • DSM-5 diagnosis of alcohol of substance abuse (other than nicotine) within the 12 months
  • DSM-5 diagnosis of alcohol or substance dependence (other than nicotine) within the last 12 months
  • DSM-5 diagnosis of personality disorder
  • Eating disorder (current or within the past 3 months)
  • Anything that, in the opinion of the investigator, would place the participant at increased risk or preclude the participant's full compliance with or completion of the study
  • Neurological disorders, including but not limited to history of seizures (except childhood febrile seizures and electro-convulsive therapy (ECT) induced seizures), dementia, history of stroke, Parkinson's disease, multiple sclerosis, cerebral aneurysm.
  • Medical or neurological illness (unstable cardiac disease, AIDS, malignancy, liver or renal impairment) or treatment for a medical disorder that could interfere with study participation
  • History of traumatic brain injury, reoccurring seizures or later cognitive rehabilitation or causing cognitive sequelae
  • History of childhood trauma (determined by the Childhood Trauma Questionnaire)
  • Prior brain surgery
  • Any brain devices/implants, including cochlear implants and aneurysm clips
  • Co-morbid neurological condition (i.e. seizure disorder, brain tumor)
  • Use of illicit drugs, confirmed by a drug test
  • Non English speakers
  • Pregnant or nursing females
  • Current use of benzodiazepines or anti-epileptic drugs
  • Inclusion Criteria for healthy controls:
  • Ages 18-65 years
  • Hamilton Depression Rating Scale score ≤8
  • Capacity to understand all relevant risks and potential benefits of the study (informed consent)
  • Negative pregnancy test for female participants
  • Exclusion Criteria for healthy controls:
  • History of major neurological or psychiatric illness, including epilepsy
  • Medication use associated with neurological or psychiatric illnesses
  • Currently undergoing counseling or psychotherapy treatment for depression, anxiety, eating disorders, PTSD or other behavioral conditions
  • DSM-5 diagnosis of personality disorder
  • First degree relative (parent, sibling, child) with major neurological or psychiatric illness
  • Prior brain surgery
  • Major head injury
  • Any brain devices/implants (including cochlear implants and aneurysm clips)
  • History of childhood trauma (determined by the Childhood Trauma Questionnaire)
  • Use of illicit drugs, confirmed by a drug test
  • Braids or other hair styling that prevents direct access to the scalp (if removal not possible)
  • Skin allergies or very sensitive skin
  • Non English speakers
  • Pregnant or nursing females

Exclusion

    Key Trial Info

    Start Date :

    September 19 2018

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    August 16 2019

    Estimated Enrollment :

    84 Patients enrolled

    Trial Details

    Trial ID

    NCT03449979

    Start Date

    September 19 2018

    End Date

    August 16 2019

    Last Update

    June 4 2020

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    University of North Carolina Chapel Hill

    Chapel Hill, North Carolina, United States, 27599